Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 14

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 14
---
s. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be harmed.
This could cause the trading price of our ordinary shares to decline, resulting in a loss of all or part of your investment. Please also
read carefully the section below titled “Cautionary Note Regarding Forward-Looking Statements.”

Risks Relating to this Offering

We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

Our management will have broad discretion in the application of the
net proceeds from this offering, including for any of the purposes described in the section titled “Use of Proceeds,”
and you will be relying on the judgment of our management regarding the application of these proceeds. You will not have the opportunity,
as part of your investment decision, to assess whether the net proceeds are being used effectively. Our management might not apply the
net proceeds in ways that ultimately increase or maintain the value of your investment. If we do not invest or apply the net proceeds
from this offering in ways that enhance shareholder value, we may fail to achieve expected financial results, which could cause the price
of our ordinary shares to decline. In addition, our failure to effectively apply the net proceeds from this offering could have a material
adverse effect on our business, results of operations, financial condition and prospects.

Our ordinary share price is and may continue to be volatile and you may not be able to resell our securities at or above the price you paid.

The market price for our ordinary shares is volatile
and may fluctuate significantly in response to a number of factors, most of which we cannot control, such as fluctuations in financial
results, our ability to advance the development of our product candidates or changes in securities analysts’ recommendations. In
addition, our ordinary shares have been and may continue to be affected by limited trading volume. Each of these factors, among others,
could harm your investment in our ordinary shares and could result in you being unable to resell the ordinary shares that you purchased
at a price equal to or above the price you paid.

If securities or industry analysts publish negative reports about our business, our share price and trading volume could decline.

The market price for our ordinary shares depends
in part on the research and reports that securities or industry analysts publish about us or our business, our market and our competitors.
We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our shares or